Preparation method of sitafloxacin related substance D-3

During the preparation of sitafloxacin, the reaction of sodium hydride and acid solution and combined with the layered extraction technology of specific solvents was optimized, and the yield was solved. and the problem of low purity achieves efficient preparation effect.

CN118955374APending Publication Date: 2024-11-15BEIJING AIKOM TECHNOLOGY CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411054724.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The yield and purity of the cetafloxacin-related substance D-3 in the prior art are low, and there is a lack of effective preparation methods to improve its quality.

Method used

By mixing compound 1 and dioxane and adding sodium hydride, adjusting pH, reacting with acid solution, and then layered extraction is performed using a specific ratio of solvent, the conditions are optimized, including temperature and concentration method, to obtain high yield and high Pure citafloxacin-related substance D-3.

Benefits of technology

The high yield and high purity preparation of the Cethafloxacin-related substance D-3 was achieved, and the basis for its quality control and subsequent research and utilization was improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004976018100000021
    Figure BDA0004976018100000021
  • Figure BDA0004976018100000051
    Figure BDA0004976018100000051
  • Figure FDA0004976018090000011
    Figure FDA0004976018090000011
Patent Text Reader

Abstract

The invention provides a preparation method of a sitafloxacin related substance D-3, and relates to the technical field of organic synthesis, the preparation method specifically comprises the following steps: (1) mixing and dissolving a compound 1 and dioxane, cooling, adding sodium hydride, stirring, adjusting pH, and concentrating to obtain a compound 2; and (2) adding the compound 2 into an acid solution for dissolving, heating for reaction, cooling, adding into water to precipitate a solid, filtering, adding the precipitated solid into a solvent A, layering to obtain a water phase, concentrating, adding ethanol, continuously stirring, finally adding a solvent B, extracting, and concentrating an organic phase to obtain the sitafloxacin related substance D-3. The solvent A comprises dichloromethane, acetonitrile and ethyl acetate, and the solvent B comprises methyl tert-butyl ether and n-heptane. According to the preparation method disclosed by the invention, the sitafloxacin related substance D-3 with high yield and high purity can be obtained.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for preparing sitafloxacin related substance D-3. Background Art

[0002] Sitafloxacin, chemically named 7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, is a broad-spectrum quinolone antibacterial drug with strong antibacterial activity against methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis, anaerobic bacteria, mycoplasma, chlamydia, etc. Its monohydrate is mostly used clinically to treat severe and refractory infectious diseases. Sitafloxacin-related substance D-3, chemically named 8-chloro-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-7-hydroxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, is one of the impurities in the degradation of sitafloxacin acid. Currently, there are few studies on this component.

[0003] Existing technologies such as literature: Chen Bin, Li Zhenye, Liu Xia, et al. Separation of sitafloxacin-related substance D-3 and analysis of its two-dimensional nuclear magnetic resonance spectrum [J]. Shanghai Medicine, 2019, 40(011): 71-74. D-3 produced during the synthesis of sitafloxacin was separated by preparative thin layer chromatography, and the separated D-3 was structurally analyzed by one-dimensional nuclear magnetic resonance spectrum and two-dimensional correlation spectrum 1H-1HCOSY, DEPT135, HSQC, and HMBC.

[0004] For example, patent CN109851557A discloses a method for preparing a sitafloxacin related substance D-3, comprising: reacting compound (V) in a mixed acid at a temperature above 90°C for more than 20 hours, and post-processing to obtain sitafloxacin related substance D-3. The synthesis method in this invention has a relatively simple synthesis route, relatively mild reaction conditions, and uses cheap and easily available raw materials and reagents, and can directly obtain more target products. However, for the related substance D-3, its yield and purity still have room for further improvement.

[0005] In view of the problems in the prior art that the sitafloxacin related substance D-3 has been less studied, has low purity and low yield, it is very necessary to find a preparation method for the sitafloxacin related substance D-3 with higher yield and purity. Summary of the invention

[0006] The present invention aims at solving the problems existing in the prior art and provides a method for preparing a sitafloxacin related substance D-3. The method can obtain the sitafloxacin related substance D-3 with high yield and high purity.

[0007] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0008] The present invention provides a method for preparing sitafloxacin related substance D-3, comprising the following steps:

[0009] (1) Compound 1 and dioxane are mixed and dissolved, the temperature is lowered, sodium hydride is added, the mixture is stirred, the pH is adjusted, and the mixture is concentrated to obtain Compound 2;

[0010] (2) adding compound 2 to an acid solution to dissolve it, heating it for reaction, cooling it, adding it to water to precipitate a solid, filtering it, and then adding the precipitated solid to solvent A, separating the layers, obtaining an aqueous phase, and concentrating it, then adding ethanol, continuing to stir, and finally adding solvent B, extracting, and concentrating the organic phase to obtain sitafloxacin related substance D-3; the solvent A includes dichloromethane, acetonitrile, and ethyl acetate, and the solvent B includes methyl tert-butyl ether and n-heptane;

[0011] The chemical reaction equation is as follows:

[0012]

[0013] It is worth noting that, in the above formula, compound 1 and compound 2 are both known intermediates of sitafloxacin.

[0014] Furthermore, in step (1), the usage ratio of compound 1, dioxane and sodium hydride is 10-30 g:150-220 ml:0.2-0.8 g.

[0015] Furthermore, the pH in step (1) is no more than 3.

[0016] In some specific embodiments, the pH is adjusted using acetic acid.

[0017] Furthermore, in step (2), the volume ratio of the acid solution, water, solvent A, ethanol and solvent B is 8-10:80-150:10-20:15-20:15-20.

[0018] Furthermore, the acid solution in step (2) comprises acetic acid and / or hydrochloric acid.

[0019] Furthermore, the heating temperature in step (2) is 95-100°C.

[0020] Furthermore, the solvent A in step (2) comprises dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 3-5:1-2:1-2.

[0021] Preferably, the solvent A in step (2) comprises dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 2:1:1.

[0022] Furthermore, the solvent B in step (2) comprises methyl tert-butyl ether and n-heptane in a volume ratio of 1-2:1-2.

[0023] Preferably, the solvent B in step (2) comprises methyl tert-butyl ether and n-heptane in a volume ratio of 1:1.

[0024] Furthermore, the cooling in step (1) and step (2) is performed to 15-20°C.

[0025] Furthermore, the concentration in step (1) and step (2) is carried out under reduced pressure at a temperature of 40-50°C, preferably 45°C.

[0026] The technical effects achieved by the present invention are:

[0027] The invention optimizes the preparation process of sitafloxacin related substance D-3, successfully prepares high-yield and high-purity related substance D-3, and plays a key role in the quality control research of sitafloxacin and the further development and utilization of related substance D-3. DETAILED DESCRIPTION

[0028] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0029] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing specific embodiments rather than for limiting the scope of protection of the present invention.

[0030] When the embodiment gives a numerical range, it should be understood that, unless otherwise specified in the present invention, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs.

[0031] It is worth noting that the raw materials used in the present invention are all common commercially available products, so their sources are not specifically limited.

[0032] Example 1

[0033] A method for preparing sitafloxacin related substance D-3, comprising the following steps:

[0034] (1) After 20 g of compound 1 and 200 ml of dioxane were mixed and dissolved, the temperature was lowered to 18° C., 0.5 g of 60% sodium hydride was slowly added, and the mixture was stirred for 30 min. Acetic acid was added to adjust the pH to below 3, and the mixture was concentrated under reduced pressure at 45° C. to obtain a concentrated solution of compound 2;

[0035] (2) The concentrated solution of compound 2 was added to 90 ml of acetic acid to dissolve it, and then heated at 95°C for 30 hours. The temperature was lowered to 18°C, and the solution was added dropwise to 1000 ml of water to precipitate a solid, which was then filtered. The precipitated solid was then added to 150 ml of solvent A (dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 2:1:1), stirred, and allowed to stand for stratification to obtain an aqueous phase, which was concentrated under reduced pressure at 45°C, and then 180 ml of ethanol was added. The stirring was continued, and finally 180 ml of solvent B (methyl tert-butyl ether and n-heptane in a volume ratio of 1:1) was added for extraction. The organic phase was concentrated under reduced pressure at 45°C to obtain sitafloxacin related substance D-3.

[0036] The chemical reaction equation is as follows:

[0037]

[0038] Example 2

[0039] A method for preparing sitafloxacin related substance D-3, comprising the following steps:

[0040] (1) After 10 g of compound 1 and 150 ml of dioxane were mixed and dissolved, the temperature was lowered to 15° C., 0.2 g of sodium hydride with a mass fraction of 60% was slowly added, and the mixture was stirred for 30 min. Acetic acid was added to adjust the pH to below 3, and the mixture was concentrated under reduced pressure at 40° C. to obtain a concentrated solution of compound 2;

[0041] (2) The concentrated solution of compound 2 was added to 80 ml of acetic acid to dissolve it, and then heated at 95°C for 30 h. The mixture was cooled to 15°C and added dropwise to 800 ml of water to precipitate a solid, which was then filtered. The precipitated solid was then added to 100 ml of solvent A (dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 3:1:1), stirred, allowed to stand for stratification, and an aqueous phase was obtained. The aqueous phase was concentrated under reduced pressure at 40°C, and 150 ml of ethanol was added. The stirring was continued, and finally 150 ml of solvent B (methyl tert-butyl ether and n-heptane in a volume ratio of 1:1) was added for extraction. The organic phase was concentrated under reduced pressure at 40°C to obtain sitafloxacin related substance D-3.

[0042] The chemical reaction equation is the same as that in Example 1.

[0043] Example 3

[0044] A method for preparing sitafloxacin related substance D-3, comprising the following steps:

[0045] (1) After 30 g of compound 1 and 220 ml of dioxane were mixed and dissolved, the temperature was lowered to 20° C., 0.8 g of 60% sodium hydride was slowly added, and the mixture was stirred for 30 min. Acetic acid was added to adjust the pH to below 3, and the mixture was concentrated under reduced pressure at 50° C. to obtain a concentrated solution of compound 2;

[0046] (2) The concentrated solution of compound 2 was added to 90 ml of acetic acid and 10 ml of concentrated hydrochloric acid to dissolve, and then heated at 100° C. for 30 h. The mixture was cooled to 20° C. and added dropwise to 1500 ml of water to precipitate a solid, which was then filtered. The precipitated solid was then added to 200 ml of solvent A (dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 5:2:2), stirred, allowed to stand for stratification, and an aqueous phase was obtained. The phase was concentrated under reduced pressure at 50° C., 200 ml of ethanol was added, stirring was continued, and finally 200 ml of solvent B (methyl tert-butyl ether and n-heptane in a volume ratio of 1:2) was added for extraction. The organic phase was concentrated under reduced pressure at 50° C. to obtain sitafloxacin related substance D-3.

[0047] The chemical reaction equation is the same as that in Example 1.

[0048] Comparative Example 1

[0049] The only difference from Example 1 is that solvent B is replaced by an equal amount of solvent A, that is, step (2) is specifically as follows:

[0050] The concentrated solution of compound 2 was added to 90 ml of acetic acid to dissolve it, and then heated at 95°C for 30 hours. The temperature was lowered to 18°C, and the solution was added dropwise to 1000 ml of water to precipitate a solid, which was then filtered. The precipitated solid was then added to 150 ml of solvent A (dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 2:1:1), stirred, and allowed to stand for stratification to obtain an aqueous phase, which was concentrated under reduced pressure at 45°C, and then 180 ml of ethanol was added, stirring was continued, and finally 180 ml of solvent A (dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 2:1:1) was added, extracted, and the organic phase was concentrated under reduced pressure at 45°C to obtain sitafloxacin related substance D-3.

[0051] Comparative Example 2

[0052] The only difference from Example 1 is that solvent A is replaced by an equal amount of solvent B, that is, step (2) is specifically as follows:

[0053] The concentrated solution of compound 2 was added to 90 ml of acetic acid to dissolve it, and then heated at 95°C for 30 hours. The temperature was lowered to 18°C, and the solution was added dropwise to 1000 ml of water to precipitate a solid, which was then filtered. The precipitated solid was then added to 150 ml of solvent B (methyl tert-butyl ether and n-heptane in a volume ratio of 1:1), stirred, and allowed to stand for stratification to obtain an aqueous phase, which was concentrated under reduced pressure at 45°C, and then 180 ml of ethanol was added, stirring was continued, and finally 180 ml of solvent B (methyl tert-butyl ether and n-heptane in a volume ratio of 1:1) was added, extracted, and the organic phase was concentrated under reduced pressure at 45°C to obtain sitafloxacin related substance D-3.

[0054] Comparative Example 3

[0055] The only difference from Example 1 is that the specific components of solvent A and solvent B are replaced, that is, step (2) is specifically as follows:

[0056] The concentrated solution of compound 2 was added to 90 ml of acetic acid to dissolve it, and then heated at 95°C for 30 hours. The temperature was lowered to 18°C, and the solution was added dropwise to 1000 ml of water to precipitate a solid, which was then filtered. The precipitated solid was then added to 150 ml of solvent A (dichloroethane, acetonitrile and ethyl acetate in a volume ratio of 2:1:1), stirred, allowed to stand for stratification, and an aqueous phase was obtained. The phase was concentrated under reduced pressure at 45°C, and 180 ml of ethanol was added. The stirring was continued, and finally 180 ml of solvent B (methyl tert-butyl ether and chloroform in a volume ratio of 1:1) was added for extraction. The organic phase was concentrated under reduced pressure at 45°C to obtain sitafloxacin related substance D-3.

[0057] Comparative Example 4

[0058] The only difference from Example 1 is that the ratios of the components in solvent A and solvent B are different, that is, step (2) is specifically as follows:

[0059] The concentrated solution of compound 2 was added to 90 ml of acetic acid to dissolve it, and then heated at 95°C for 30 hours. The temperature was lowered to 18°C, and the solution was added dropwise to 1000 ml of water to precipitate a solid, which was then filtered. The precipitated solid was then added to 150 ml of solvent A (dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 2:3:0.5), stirred, allowed to stand for stratification, and an aqueous phase was obtained. The phase was concentrated under reduced pressure at 45°C, and 180 ml of ethanol was added. The stirring was continued, and finally 180 ml of solvent B (methyl tert-butyl ether and n-heptane in a volume ratio of 0.5:2.5) was added for extraction. The organic phase was concentrated under reduced pressure at 45°C to obtain sitafloxacin related substance D-3.

[0060] The weight of the sitafloxacin related substance D-3 in each embodiment and comparative example was weighed, and the yield and purity of the sitafloxacin related substance D-3 were calculated by HPLC to obtain the following table:

[0061] Table 1 Yield and purity of sitafloxacin related substance D-3 in Examples and Comparative Examples

[0062] Examples Yield (%) purity(%) Example 1 32.6 98.9 Example 2 30.3 98.0 Example 3 31.5 98.7 Comparative Example 1 26.5 96.4 Comparative Example 2 27.3 94.8 Comparative Example 3 20.1 95.5 Comparative Example 4 28.5 88.6

[0063] According to the results of the above table, the yield and purity of the sitafloxacin related substance D-3 in the present invention are improved, which is a great progress compared with the prior art, and provides a basic guarantee for the further study of the sitafloxacin related substance D-3. In comparison, when the extraction solvent of the two-step extraction is changed, the corresponding yield or purity of the product will change greatly, and both show a significant decrease.

[0064] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A method for preparing sitafloxacin related substance D-3, characterized in that: The following steps are involved: (1) Compound 1 and dioxane are mixed and dissolved, the temperature is lowered, sodium hydride is added, the mixture is stirred, the pH is adjusted, and the mixture is concentrated to obtain Compound 2; (2) adding compound 2 to an acid solution to dissolve it, heating it for reaction, cooling it, adding it to water to precipitate a solid, filtering it, and then adding the precipitated solid to solvent A, separating the layers, obtaining an aqueous phase, and concentrating it, then adding ethanol, continuing to stir, and finally adding solvent B, extracting, and concentrating the organic phase to obtain sitafloxacin related substance D-3; the solvent A includes dichloromethane, acetonitrile, and ethyl acetate, and the solvent B includes methyl tert-butyl ether and n-heptane; The chemical reaction equation is as follows:

2. The preparation method according to claim 1, characterized in that: The usage ratio of compound 1, dioxane and sodium hydride in step (1) is 10-30g:150-220ml:0.2-0.8g.

3. The preparation method according to claim 1, characterized in that: The pH in step (1) is no more than 3.

4. The preparation method according to claim 1, characterized in that: The volume ratio of the acid solution, water, solvent A, ethanol and solvent B in step (2) is 8-10:80-150:10-20:15-20:15-20.

5. The preparation method according to claim 1, characterized in that: The acid solution in step (2) includes acetic acid and / or hydrochloric acid.

6. The preparation method according to claim 1, characterized in that: The heating temperature in step (2) is 95-100°C.

7. The preparation method according to claim 1, characterized in that: The solvent A in step (2) comprises dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 3-5:1-2:1-2.

8. The preparation method according to claim 7, characterized in that: The solvent A in step (2) comprises dichloromethane, acetonitrile and ethyl acetate in a volume ratio of 2:1:

1.

9. The preparation method according to claim 1, characterized in that: The solvent B in step (2) comprises methyl tert-butyl ether and n-heptane in a volume ratio of 1-2:1-2.

10. The preparation method according to claim 9, characterized in that: The solvent B in step (2) comprises methyl tert-butyl ether and n-heptane in a volume ratio of 1:1.

Citation Information

Patent Citations

  • Highly absorbable solid preparations containing sitafloxacin and tartaric acid

    CA2417764A1

  • Method for preparing Moxifloxacin impurity C

    CN104945399A

  • Preparation method of citafloxacin-related substance D-3

    CN109851557A

  • Highly absorbable solid preparation

    CN1444480A

  • Highly absorptive solid preparation

    US20030176452A1